ClinicalTrials.gg
CompletedNCT05749731EU-COGERUpdated Mar 1, 2023

Pan-European Study on Geriatric Rehabilitation After COVID-19 Disease

An observational study in COVID-19, sponsored by Leiden University Medical Center. Completed at 51 sites in 10 countries. Per ClinicalTrials.gov, last updated 2023-03-01.

Sponsored by Leiden University Medical Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
723
Sex
All
01

Study summary

Older and more vulnerable persons are more likely to get very ill when infected with the coronavirus, and have the highest COVID-19 morbidity and mortality rate. The majority of patients that are admitted to the hospital are older (>70 years), and some of them have been admitted to Intensive Care Units (ICU). In the case of rehabilitation of older patients post-COVID-19, we do not know what the course of recovery for these patients will be, and what treatment/approaches will deliver the best outcomes.

Persons that are recovering from a COVID-19 infection, and admitted on a geriatric ward for early rehabilitation, or geriatric rehabilitation ward or facility, can be included in the study. They will receive routine, usual care; participation in this study will not affect their rehabilitation care. Routine care data will be collected from their electronic patient files at admission to geriatric rehabilitation, and at discharge. This also includes some data about their premorbid status. In addition, study participants will be called six weeks and six months after discharge from rehabilitation and asked some questions about their recovery. There is no risk association with participation in this study. Data will be anonymously collected in an online database.

The primary aim of this study is to get insight into the course of recovery in (geriatric) rehabilitation patients affected by COVID-19 in Europe. Mainly, we are interested in functioning in activities of daily living (ADL-functioning) such as toileting, bathing, dressing, etc., and in quality of life. The second aim of this study is to get insight into the treatment modalities employed and the organization of geriatric rehabilitation that post-COVID patients in Europe receive. Therefore, we collect data on the types of care provided and the professionals involved. Moreover, we collect some patient characteristics such as year of birth, gender, date of admission and date of discharge; and data about complications such as delirium, pain, post-traumatic stress syndrome, hospital readmissions, and mortality. Our hypothesis is that most patients will show recovery during geriatric rehabilitation and in the six months after. However, we expect that the amount and/or speed of recovery will vary between patients.

Read the detailed description

INTRODUCTION AND RATIONALE The COVID-19 pandemic has hit the world hard, and older and vulnerable persons are more likely to get very ill when infected, and have the highest morbidity and mortality. The majority of patients that are admitted to the hospital are older (>70 years), and some of them have been, or are being, admitted to Intensive Care Units. Many patients stay on the ICU/hospital for weeks. To get back to the highest state of functional independence, these patients will need specialised care and treatment, therefore geriatric rehabilitation will be very likely required.

Geriatric Rehabilitation (GR) is defined as a multidimensional approach of diagnostic and therapeutic interventions, the purpose of which is to optimise functional capacity, promote activity and preserve functional reserve and social participation "in older people with disabling impairments." The goal of geriatric rehabilitation has been defined as "to assist [older people] to manage personal activities of daily living without the assistance of another person. If this is not possible, the goal is to minimize the need for external assistance through the use of adaptive techniques and equipment." Thereby focussing on the amelioration of dependency in activities of daily living. However, we are still in the dark about the amount of functional recovery of geriatric post-COVID-19 patients. We do know from the first lessons from Italy, that the rehabilitation process is difficult, and the course is capricious.

Before being able to assure the best outcomes for older post-COVID geriatric rehabilitation patients, we first have to be informed about what the clinical characteristics are, what treatment is provided, and what outcomes geriatric post-COVID-19 patients have in geriatric rehabilitation. Therefore, members of the Special Interest Group Geriatric Rehabilitation of the European Geriatric Medical Society (EuGMS) decided to conduct this multi-center observational cohort study into usual care data on the course of functional and clinical outcomes in post-COVID-19 geriatric rehabilitation patients in several European countries.

OBJECTIVES The primary objective of this study to get insight into the course of functional and medical recovery in (geriatric) rehabilitation patients affected by COVID-19 in Europe. The secondary objective is to get insight into the treatment modalities employed and the organisation of geriatric rehabilitation that post-COVID patients in Europe receive.

The study was conducted according to the principles of the Declaration of Helsinki (2013 version) and in accordance with the General Data Protection Regulation (GDPR) and in full conformity to any applicable state or local regulations in the participating countries.

RECRUITMENT In principle, patients admitted for geriatric rehabilitation due to COVID-19 morbidity will be informed by letter and asked if they have objections that their regular care data will be anonymously used for research purposes to improve practice in geriatric rehabilitation. If they do, the data will not be used (opt-out procedure). In some countries this will be conducted under the guidelines for service evaluation and audit, as it uses routine data, held entirely by the clinical care team. Where this is not possible because of local legislation or guidelines, informed consent will be obtained (opt-in procedure). During one-year (October 2020 - November 2021), patients were enrolled in the study.

Participants will receive standard rehabilitation treatment according to the discretion of clinical teams, which will likely be adapted to the specific needs of post-COVID-19 patients. This treatment includes physical therapy, occupational therapy, and medical treatment by an advanced nursing practitioner, geriatrician or medical specialist. This study will not influence any therapy provided or decisions about the medical treatment or treatment programs already used in the participating geriatric rehabilitation setting.

This study is observational and it is not anticipated that the observations will influence therapy or treatment, particularly since such indices, questionnaires and measurements are a regular part of the rehabilitation program.

STUDY MANAGEMENT For each participating geriatric rehabilitation facility in Europe one instructed local care professional will complete an online CASTOR database in which anonymous data from the clinical records of the included patients will be collected at admission, discharge and 6 weeks and 6 months follow-up. For countries with multiple participating sites, a country coordinator was appointed. Most country coordinators were the members of the Special Interest Group Geriatric Rehabilitation of the EuGMS.

DATA COLLECTION Variables collected

  • Demographic factors: In all participants, selected demographic factors such as year of birth/age, gender, and residency premorbid will be documented.
  • Information from hospital / general practitioner: hospital length of stay (days), ICU length of stay (days), complications during hospital stay or at home (Thromboembolism, Delirium, Pressure Ulcer), and COVID-19 diagnosis confirmed (PCR, Serology, clinically)
  • At admission in geriatric rehabilitation: In all participants, only already routinely collected data will be documented. Such as ADL (Barthel index), quality of life (EQ-5D-5L), frailty (Clinical Frailty Scale), body mass index (BMI), nutritional status (MNA/NRS/MUST/SNAQ65/..), comorbidity (wFCI (0-36 pts)), cognition (MMSE/Demtect/ MOCA)) , delirium (DOS/SQiD), mood/anxiety (/GDS/HADS), pressure ulcer (yes/no), fatigue (VAS-scale), dyspnoea (VAS-scale), pain (NRS-P), mobility/balance (Timed Up and Go), muscle strength (MRC biceps /quadriceps), and speech/swallowing problems (yes/no)
  • At discharge from geriatric rehabilitation: At discharge information about: hospital readmissions, length of stay in GR, discharge destination, ADL, frailty, BMI, nutrition, cognition, mood/anxiety, fatigue, dyspnoea, pain, mobility/balance, muscle strength, quality of life and complications during GR stay (Thromboembolism, Delirium, Pressure Ulcer) will be documented. At discharge we will additionally collect information about which professionals have been involved during geriatric rehabilitation an which treatment interventions have been applied.
  • Follow-up after discharge: At 6 weeks and 6 months follow-up, and if desirable at flexible time points following regular care in the participating countries, we will document: ADL, Quality of life, post-traumatic stress syndrome.
  • Qualitative data about countries' GR care services and triage systems: country coordinators in the study filled in a questionnaire about in what facility types GR for post-COVID-19 patients is provided (e.g. nursing homes, skilled nursing facility, acute care hospital ward, or on outpatient basis), which person refers the post-COVID-19 patients to GR (e.g. physician in the hospital, or GP), at which moment the referral takes place, which patient characteristics the referral is based on (e.g. standardized age cut-offs, frailty, multimorbidity, functional status, or psychosocial needs), which formal assessment is used for GR referral decisions, additional selection criteria by health insurance/policies, and criteria that need to be met by post-COVID patients for discharge from GR.

Data checks Data checks were performed during data collection to prepare for the steering board meetings that were held every two to three months with the country coordinators. In order to stimulate the achievement of the sample size, numbers of patients included were discussed during these meeting. Also structural missing or other remarkable things in the data were discussed during these meetings. Local care professionals were made aware of other missings or outliers in the data via email and asked to check and if possible complete or correct these data.

Sample Size calculation The primary outcomes are ADL functioning (Barthel index or derived from the USER or FIM) and quality of life (EQ-5D-5L). We performed a power calculation for a paired sample t-test on the primary outcome ADL-functioning (Barthel index). We assume a minimal clinically important difference of 2 points on the Barthel index as relevant, this is the mean difference between Barthel score at admission and Barthel score at discharge. The study would require a sample size of 52 (number of pairs) to achieve a power of 80% and a level of significance of 5% (two sided), for detecting a mean of the differences of 2 between pairs, assuming the standard deviation of the differences to be 5. We wanted to include a minimum of 52 patients per country which was agreed by the special interest group SIG EuGMS as being appropriate to generate the data we require. We aimed for a minimum of 250 participants in total.

STATSISTICAL ANALYSIS Different techniques will be used to analyze the data: Descriptive statistics will be used to give an overview of characteristics of the participants in the participating countries for all primary and secondary outcomes.

  • For cross-country comparisons, we will perform a paired sample student t-test will be used to test the difference between ADL functioning at admission and follow-up per participating country, multilevel models will be built to model the recovery (in various outcome measures) of patients over time per country, supplemented with qualitative data about the countries' GR care services and triage systems.
  • The course of recovery of post-COVID-19 patients over time (in various outcome measures) will be modelled with multilevel unconditional growth models. These multilevel models take into account that measurements are nested in patients and that patients are nested in countries. In doing so, the model with the best fitting shape (e.g. linear or quadratic) to our data will reveal the amount and speed of recovery.
  • The impact of frailty on this course of recovery will be modelled, by adding the variable for frailty measured by the clinical frailty scale (CFS) to the models for the course of recovery.
  • The impact of experiencing delirium during or prior to GR on this course of recovery will be modelled, by adding the variable delirium (yes/no) to the models for the course of recovery.
  • (Potential) confounders of the impact of frailty on course of recovery and of the impact of delirium on the course of recovery such as age, sex, frailty status, delirium, and hospital stay, will be added to these
  • By using descriptive statistics it will be described which post-COVID-19 GR patients receive which therapies/interventions during GR, and/or which professionals are involved in their GR trajectory.

No imputation will be used for missing data; complete case analysis will be performed, under the assumption that the data is missing at random.

The level of significance will be set at p \< 0.05.

02

Conditions studied

  • COVID-19

Browse trials for

03

In context

COVID-19

7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.

This study's enrollment of 723 is above the median of 268 across 3,208 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Leiden University Medical Center is the lead sponsor of 334 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will be recruited from geriatric rehabilitation settings in the participating European countries (Czech Republic, Germany, Ireland, Israel, Italy, Malta, the Netherlands, Russia, Spain, United Kingdom) and consists of patients rehabilitating after a COVID-19 infection in these countries. There were no selection criteria concerning health or demographic characteristics.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recovering from a COVID-19 infection (confirmed with PCR, Serology, or clinically).
  • Indication for geriatric rehabilitation

Exclusion criteria

Exclusion Criteria:

  • Presence of severe cognitive impairment, which leads to insufficient decisional capacities to participate in the study.
  • Subjects who have opted for not using their anonymous data for research purposes
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
723 participants (actual)
Patient registry
No

Groups and cohorts

  • post-COVID-19 patients in geriatric rehabilitation

    Patients in European geriatric rehabilitation departments as the result of COVID-19 disease.

06

What researchers measure

Primary outcomes

  1. change in Activities of Daily Living (ADL)-functioning

    The primary outcome measure is: ADL functioning. ADL functioning will be assessed with the Barthel Index (BI; scale 0-20 with 0 for complete dependence and 20 for optimal independence).

    Time frame: Change in ADL-functioning from two weeks before admission to geriatric rehabilitation, until approximately 6 months after discharge from geriatric rehabilitation

Secondary outcomes

  1. change in Quality of Life (EQ-5D-5L)

    Data about quality of life is collected using the 5-level EQ-5D (EQ-5D-5L; score of maximum 1 for best possible health state) \[8\].

    Time frame: Change in quality of life from admission to geriatric rehabilitation until approximately 6 months after discharge from geriatric rehabilitation

Other outcomes

  1. length of stay in geriatric rehabilitation

    difference between admission date and discharge date

    Time frame: Date of discharge from geriatric rehabilitation minus data of admission to geriatric rehabilitation

  2. discharge destination

    cross-sectional outcome at the moment of discharge: destination of the patient at discharge from geriatric rehabilitation categorized as own home, assisted living, nursing home, hospital, deceased, or other.

    Time frame: discharge destination is collected at discharge from geriatric rehabilitation (T2).

  3. mortality

    If the patient dies during geriatric rehabilitation or during follow-up until six months after discharge from the geriatric rehabilitation department, date of death is collected.

    Time frame: date of death can be entered during geriatric rehabilitation (T2), at 6 weeks follow-up (T3), and at 6 months follow-up (T4).

  4. complications during rehabilitation

    cross-sectional outcome at the moment of discharge: if the patient experienced thromboembolism, delirium, pressure ulcer, or other complications during geriatric rehabilitation, this is recorded. (yes/no)

    Time frame: complications that occured between admission and discharge from geriatric rehabilitation.

  5. post traumatic stress disorder (PTSD)

    During the follow-up telephonic interviews, the patient is asked if he/she has developed PTSD (yes/no)

    Time frame: PTSS is collected collected at 6 weeks follow-up (T3), and at 6 months follow-up (T4).

07

Study locations

51 sites
  • Vseobecna fakultní nemocnice
    Nové Město, Czechia
  • Agaplesion Bethanien Hospital
    Heidelberg, Germany
  • Geriatrisches Zentrum Karlsruhe
    Karlsruhe, Germany
  • Geriatrische Rehabilitationsklinik Diakonissenkrankenhaus Mannheim
    Mannheim, Germany
  • Robert-Bosch-Krankenhaus
    Stuttgart, Germany
  • Beaumont Hospital
    Dublin, Ireland
  • University of Limerick Hospital Group (ULHG)
    Limerick, Ireland
  • Fliman geriatric rehabilitation center
    Haifa, Israel
  • IRCCS Istituti Clinici Maugeri
    Milan, Italy
  • Karin Grech Hospital
    Valletta, Malta
  • TriviumMeulenbeltZorg
    Almelo, Netherlands
  • Vivium Flevoburen (Zorggroep Almere)
    Almere, Netherlands
  • Icare - De Boshof
    Assen, Netherlands
  • Zorggroep Maas en Waal
    Beneden-Leeuwen, Netherlands
  • De Betuwe, Zorgcentrum Beatrix
    Culemborg, Netherlands
  • Attent
    De Steeg, Netherlands
  • Pieter van Foreest
    Delft, Netherlands
  • Van Neynsel
    Den Bosch, Netherlands
  • Florence
    Den Haag, Netherlands
  • Archipel Zorggroep
    Eindhoven, Netherlands
  • Kennemerhart Schoterhof
    Haarlem, Netherlands
  • Reactiveringscentrum Klimop
    Harderwijk, Netherlands
  • Meriant (Alliade)
    Heerenveen, Netherlands
  • TriviumMeulenbeltZorg
    Hengelo, Netherlands
  • SVRZ 't Gasthuis
    Middelburg, Netherlands
  • Zorgspectrum Nieuwegein
    Nieuwegein, Netherlands
  • Laurens Intermezzo Zuid
    Rotterdam, Netherlands
  • Argos Zorggroep
    Schiedam, Netherlands
  • Patyna
    Sneek, Netherlands
  • Careyn
    Spijkenisse, Netherlands
  • Azora
    Terborg, Netherlands
  • de Wever
    Tilburg, Netherlands
  • Liemerije
    Zevenaar, Netherlands
  • Sensire
    Zutphen, Netherlands
  • Moscow Rehabilitation center
    Moscow, Russian Federation
  • Russian Clinical and Research Center of Gerontology
    Moscow, Russian Federation
  • Consorci Sanitari Alt'Pènedes i Garraf
    Barcelona, Spain
  • Hospital de Barcelona
    Barcelona, Spain
  • Parc de Salut Mar
    Barcelona, Spain
  • Parc Sanitari Pere Virgili
    Barcelona, Spain
  • Hospital Guadarrama
    Madrid, Spain
  • Hospital La Cruz Roja
    Madrid, Spain
  • Hospital San Joan de Deu Mallorca
    Palma De Mallorca, Spain
  • Hospital Universitari Sant Joan de Reus
    Reus, Spain
  • Derbyshire Community Health Services
    Chesterfield, United Kingdom
  • University Hospitals of Derby and Burton
    Derby, United Kingdom
  • Frimley NHS Trust
    Frimley, United Kingdom
  • Harrogate District Hospital
    Harrogate, United Kingdom
  • Calderdale & Huddersfield
    Huddersfield, United Kingdom
  • Imperial College Healthcare NHS Trust
    London, United Kingdom
  • Sheffield teaching Hospitals
    Sheffield, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Researchers who wish to conduct additional analyses, for example country-specific analyses, can apply for EU-COGER research data by sending an application to P.I. prof. Wilco Achterberg (W.P.Achterberg@lumc.nl). A standardized application form is available. Applications will be judged based on the originality of the research question and the feasibility of the analysis plan. When the application is approved, a data transfer agreement (DTA) will be signed to ensure that the receiving party will adhere to our co-authorship policy and will not share the data with third parties (and will store the data in line with the General Data Protection Regulation (GDPR), in case of non-EU member states). After the DTA has been signed, the research data will be shared in line with the GDPR and permission provided in the informed consent forms. We will use multi-factor authentication to ensure that no unintended persons will be able to access the data transfer.

Supporting information: Study protocol

Time frame: Data is currently available on request (see plan description)

Access criteria: see Plan Description

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jul 2022, 21 months.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 21 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2023
First posted
Mar 1, 2023
StartActual
Oct 1, 2020
Primary completionActual
Jul 31, 2022
CompletionActual
Jul 31, 2022
Last update
Mar 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05749731
Collaborators
Leids Universiteits Fonds, ZonMw: The Netherlands Organisation for Health Research and Development
Responsible party
mlhaaksma (Senior researcher, Leiden University Medical Center) — Principal investigator
First posted
Mar 1, 2023
Start date
Oct 1, 2020
Primary completion
Jul 31, 2022
Completion
Jul 31, 2022
Last update
Mar 1, 2023

Study contacts

Monique AA Caljouw, Dr.
study chair · Department of Public Health and Primary Care, Leiden University Medical Cente
Wilco P Achterberg, Prof.
principal investigator · Department of Public Health and Primary Care, Leiden University Medical Cente

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion